Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. When Making Your Bed Feels Like Running a Marathon: Understanding Exercise Limitation in Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Pooja Dewan
  • Rasmus Rørth
  • Valeria Raparelli
  • Ross T Campbell
  • Li Shen
  • Pardeep S Jhund
  • Mark C Petrie
  • Inder S Anand
  • Peter E Carson
  • Akshay S Desai
  • Christopher B Granger
  • Lars Køber
  • Michel Komajda
  • Robert S McKelvie
  • Eileen O'Meara
  • Marc A Pfeffer
  • Bertram Pitt
  • Scott D Solomon
  • Karl Swedberg
  • Michael R Zile
  • John J V McMurray
Vis graf over relationer

BACKGROUND: To describe characteristics and outcomes in women and men with heart failure with preserved ejection fraction.

METHODS: Baseline characteristics (including biomarkers and quality of life) and outcomes (primary outcome: composite of first heart failure hospitalization or cardiovascular death) were compared in 4458 women and 4010 men enrolled in CHARM-Preserved (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) (EF≥45%), I-Preserve (Irbesartan in heart failure with Preserved ejection fraction), and TOPCAT-Americas (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial).

RESULTS: Women were older and more often obese and hypertensive but less likely to have coronary artery disease or atrial fibrillation. Women had more symptoms and signs of congestion and worse quality of life. Despite this, the risk of the primary outcome was lower in women (hazard ratio, 0.80 [95% CI, 0.73-0.88]), as was the risk of cardiovascular death (hazard ratio, 0.70 [95% CI, 0.62-0.80]), but there was no difference in the rate for first hospitalization for heart failure (hazard ratio, 0.92 [95% CI, 0.82-1.02]). The lower risk of cardiovascular death in women, compared with men, was in part explained by a substantially lower risk of sudden death (hazard ratio, 0.53 [0.43-0.65]; P<0.001). E/A ratio was lower in women (1.1 versus 1.2).

CONCLUSIONS: There are significant differences between women and men with heart failure with preserved ejection fraction. Despite worse symptoms, more congestion, and lower quality of life, women had similar rates of hospitalization and better survival than men. Their risk of sudden death was half that of men.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00853658, NCT01035255.

OriginalsprogEngelsk
TidsskriftCirculation. Heart failure
Vol/bind12
Udgave nummer12
Sider (fra-til)e006539
ISSN1941-3289
DOI
StatusUdgivet - dec. 2019

ID: 59124094